Alerts will be sent to your verified email
Verify Email
BETA
|
Beta Drugs
|
Bliss GVS Pharma
|
Syncom Formulations
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
21.73 % | 6.83 % | 8.81 % |
|
5yr Avg Net Profit Margin
|
11.97 % | 8.7 % | 7.78 % |
|
Price to Book
|
0.0 | 1.59 | 4.61 |
|
P/E
|
44.76 | 15.66 | 27.4 |
|
5yr Avg Cash Conversion Cycle
|
15.7 Days | 186.56 Days | 84.02 Days |
|
5yr Average Interest Coverage Ratio
|
13.71 | 14.68 | 39.83 |
|
5yr Avg ROCE
|
27.85 % | 13.27 % | 12.74 % |
|
5yr Avg Operating Profit Margin
|
21.58 % | 17.03 % | 9.47 % |
|
5 yr average Debt to Equity
|
0.23 | 0.11 | 0.2 |
|
5yr CAGR Net Profit
|
31.07 % | 4.24 % | 19.56 % |
|
5yr Average Return on Assets
|
12.53 % | 5.31 % | 5.89 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
66.73 % | 35.44 % | 50.57 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.02 % | 0.93 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Beta Drugs
|
Bliss GVS Pharma
|
Syncom Formulations
|
|---|